CytoMed Therapeutics Limited/$GDTC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
- Ticker
- $GDTC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 42
- Headquarters
- Singapore, Singapore
- Website
- w2.cytomed.sg
GDTC Metrics
BasicAdvanced
$10M
-
-$0.23
0.07
-
Price and volume
Market cap
$10M
Beta
0.07
52-week high
$2.29
52-week low
$0.68
Average daily volume
17K
Financial strength
Current ratio
2.644
Quick ratio
1.506
Long term debt to equity
0.073
Total debt to equity
0.084
Interest coverage (TTM)
-192.87%
Profitability
EBITDA (TTM)
-2.769
Gross margin (TTM)
85.89%
Net profit margin (TTM)
-444.48%
Operating margin (TTM)
-506.87%
Revenue per employee (TTM)
$15,560
Management effectiveness
Return on assets (TTM)
-32.52%
Return on equity (TTM)
-56.17%
Valuation
Price to revenue (TTM)
16.166
Price to book
2.02
Price to tangible book (TTM)
2.06
Price to free cash flow (TTM)
-2.976
Free cash flow yield (TTM)
-33.60%
Free cash flow per share (TTM)
-0.282
Growth
Revenue change (TTM)
8.11%
Earnings per share change (TTM)
-6.73%
3-year revenue growth (CAGR)
11.22%
3-year earnings per share growth (CAGR)
-14.83%
GDTC Financial Performance
Revenues and expenses
GDTC Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.